🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "huge turning point" in the effort against drug-resistant strains of the bacteria, according to health experts.

A Global Public Health Issue

Cases of gonorrhoea are escalating around the world, with data suggesting over 82 million infections annually. Particularly high rates are observed in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Secure Clearance

Zoliflodacin, alternatively called Nuzolvence, was authorized by the US FDA in recent days for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts believe that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Outcomes and Global Access

As per results detailed in a prominent scientific publication, the new drug cured over nine in ten of cases of the STI. This places it at an equal footing with the typical regimen, which involves two antibiotics. The trial involved hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to make available and distribute the drug in many developing nations.

Clinicians directly involved have voiced positive views. Access to a easy-to-administer therapy such as this is seen as a "critical tool" for managing the epidemic. This is deemed essential to alleviate the strain of the disease for patients and to halt the transmission of highly drug-resistant gonorrhoea globally.